乙肝病毒的治疗现状及其未来展望
摘要
关键词
全文:
PDF参考
王虹.药物抗病毒治疗慢乙肝的最新研究进展[J].黑龙江医 学,2021,45(13):1456-1457.
樊蓉,孙剑,侯金林.慢性乙型肝炎抗病毒治疗现状及展望[J].临 床肝胆病杂志,2016,32(11):2029-2032.
金丽,苏强,周建华,等.I型和III型干扰素抗病毒作用机制的研 究进展[J].中国生物制品学杂志,2021,34(4):481-486.
Marco De Andrea. The interferon system: an overview[J]. European Journal of Paediatric Neurology,2002(6):41-46.
郭素娟,李智伟.聚乙二醇与普通干扰素治疗HBeAg阳性慢性乙 型肝炎的疗效[J].肝脏,2016,21(2):119-122.
郑娟,刘威龙,舒丹,等.慢乙肝抗HBV病毒治疗的现状和研究进 展[J].热带医学杂志,2017,17(4):546-551.
王新军.长效干扰素与普通干扰素治疗慢性乙肝的成本—效果 比较[J].现代中西医结合杂志,2014,23(12):1300-1302.
Lampertico P, Vigan M, Di Costanzo Gg, et al. Ran-domised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B[J]. Gut,2013,62(2):290-298.
Wang C, Chen J, Sun J. Entecavir for treatment of lamivudine- refractory chronic hepatitis b[EB/OL]. Medical Journal of Chinese People’s Liberation Army. http://wprim.whocc.org. cn/admin/article/articleDetail?WPRIMID=563457&article Id=563457,1983-1-1.
Robinson, D M, Scott, et al. Entecavir[EB/OL]. Drugs. https:// link.springer.com/article/10.2165/00003495-200666120- 00009,2012-9-12.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infec-tion[J]. J Hepatol,2012,57(1):167-185.
Liu MA. DNA vaccines: an historical perspective and view to the future[J]. Immunol Rev,2011,239(1):62-84.
杨富强,饶桂荣.乙型肝炎治疗性疫苗研究进展[J].传染病信 息,2015,28(2):65-69.
Xu DZ, Wang XY, Shen XL, et al. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vac- cine for chronic hepatitis B patients: experiences and findings[J]. J Hepatol,2013,59(3):450-456.
Yang SH, Lee CG, Park SH, et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study[J]. Gene Ther,2006,13(14):1110- 1117.
Yang FQ, Yu YY, Wang GQ, et al. A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo elec- troporation in chronic hepatitis B patients under lamivudine chem- otherapy[J]. J Viral Hepat,2012,19(8):581-593.
陈姝,兰英华,李用国.树突状细胞与乙肝慢性化的关系及树 突状细胞疫苗相关研究进展[J].国际免疫学杂志,2009,32(6): 446-449.
Qasim W, Brunetto M, Gehring AJ, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, tar-geting HBsAg in a liver transplant patient[J]. J Hepatol,2015,62(2):486-491.
Livingston BD, Alexander J, Crimi C, et al. Altered helper T lym-phocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans[J]. J Immunol,1999,162(5):3088-3095.
Shi TD, Wu YZ, Jia ZC, et al. Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+CTL-mediated cytoto-xicity in HLA-A2+human PBMCs[J]. World J Gastroenterol, 2004,10(13):1902-1906.
Hannon G J. RNA interference[J]. Nature,2002,418(6894):244-251. [22] Paddison P J, Caudy A A, Bernstein E, et al. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells[J]. Genes Dev,2002,16(8):948-958.
Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing[J]. Nature,2003,425(6956):415-419.
Mocellin S, Costa R, Nitti D. RNA interference: ready to silence cancer?[J]. J Mol Med,2006,84(1):4-15.
Romano P R, McCallus D E, Pachuk C J. RNA interferencemediated prevention and therapy for hepatocellular carcinoma[J]. Oncogene,2006,25(27):3857-3865.
张学智,山长亮,叶丽虹,等.RNA干扰在抗乙肝治疗中的应用及其研究进展[J].生物化学与生物物理进展,2008(6):631-636.
DOI: https://doi.org/10.12346/pmr.v3i6.4887
Refbacks
- 当前没有refback。